Arrowhead accelerates funding of Insert Therapeutics

Oct. 11, 2005 – Arrowhead Research Corp. (Nasdaq:ARWR), a company that funds nanotechnology research and develops companies, announced it accelerated its investment of an additional $3 million to Insert Therapeutics Inc., a majority-owned subsidiary.

The company says its lead anti-cancer drug, IT-101, has showed promise across a wide range of cancers. Insert Therapeutics is currently preparing to enter IT-101 into human clinical trials at the City of Hope Comprehensive Cancer Center in Duarte, Calif.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.